Cargando…
MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia
Over the past decades numerous markers of the tumor burden have been discovered in chronic lymphocytic leukemia (CLL). Among these, the microRNAs seem to have a promising role. The development and validation of miRNAs as biomarkers should have significant impact in improving early cancer detection a...
Autores principales: | Visone, Rosa, Veronese, Angelo, Balatti, Veronica, Croce, Carlo M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326649/ https://www.ncbi.nlm.nih.gov/pubmed/22350310 |
Ejemplares similares
-
HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia
por: Pagotto, Sara, et al.
Publicado: (2019) -
Role of microRNA in chronic lymphocytic leukemia onset and progression
por: Balatti, Veronica, et al.
Publicado: (2015) -
The Glucose-Regulated MiR-483-3p Influences Key Signaling Pathways in Cancer
por: Pepe, Felice, et al.
Publicado: (2018) -
miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eμ-TCL1 mouse model
por: Bresin, Antonella, et al.
Publicado: (2015) -
Is miR-29 an oncogene or tumor suppressor in CLL?
por: Pekarsky, Yuri, et al.
Publicado: (2010)